Dava Stewart

A research team from the Netherlands turns to deep sequencing technology to detect hepatitis C virus resistant variants.

The retrospective study included a cohort of patients from six countries across Europe who were diagnosed with HCV and received daclatasvir during the Named Patient Program.

According to the Belgian researchers, Sofosbuvir in combination with simeprevir with or without ribarivirn was found to be well-tolerated and efficacious.

A research group from Hokkaido University in Japan found that standard treatment for those with genotype 1 HCV should likely be switched from interferon (INF)-based therapies to INF-free direct-acting antiviral (DAA) therapies.

Felix Kleefeld, of Berlin, Germany, and colleagues examined how eradicating HCV affected the cognition of patients in a study published in Neurology in December 2016.

Researchers conducted a post hoc analysis to learn whether or not the length of time it took to attain initial viral suppression is related to sustained virologic response (SVR) rates for patients receiving the so-call 3D treatment, with or without ribavirin.